@entity136 , XXXX , and @entity27308 : a phase I study.

@entity1 @entity137 @entity5 @entity1311 @entity2592 @entity1606 @entity27308 @entity1499 @entity136
@entity27308 is a new antifolate that has shown activity in @entity1499 -resistant @entity5 . @entity136 is an antimetabolite similar in structure to @entity2592 with early studies demonstrating activity in a variety of @entity5 . It also has apparent synergistic activity with antifolates from initial work in @entity5 models. @entity1311 is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid @entity5 . The combination of @entity136 , @entity1311 , and @entity27308 was assessed in this phase I trial. Thirty @entity1 were enrolled. The starting doses were @entity27308 25 mg orally twice daily (days 1-4, 15-18), @entity1311 75 mg/m2 (days 1, 15), and @entity136 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four @entity1 achieved stable disease while on study, whereas one @entity1 with a poorly differentiated @entity5 achieved a partial response. The main @entity137 was myelosuppression. The maximum tolerated dose was thought to be @entity27308 25 mg orally three times daily (days 1-4), @entity1311 150 to 175 mg/m2 (days 1, 15), and @entity136 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with @entity1311 and @entity136 appears safe and should be considered for phase II trials in known @entity5 such as @entity1606 .
